Premium
Subcutaneous bortezomib combined with weekly cyclophosphamide and dexamethasone is an efficient and well tolerated regime in newly diagnosed multiple myeloma
Author(s) -
Ong ShinYeu,
Ng Hong Yen,
Surendran Shilpa,
Linn Yeh Ching,
Chen YunXin,
Goh Yeow Tee,
Diong Colin,
Gopalakrishnan Sathish Kumar
Publication year - 2015
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.13238
Subject(s) - bortezomib , cyclophosphamide , dexamethasone , medicine , multiple myeloma , thalidomide , lenalidomide , dosing , oncology , pharmacology , chemotherapy
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom